Compare Lululemon Athletica Inc (LULU) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lululemon Athletica Inc vs Zimmer Biomet Holdings Inc — how do they compare? Lululemon Athletica Inc trades at $94.5 (market cap $10.27B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Lululemon Athletica Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lululemon Athletica Inc for 105 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| LULU | ZBH | |
|---|---|---|
Market Cap | $10.27B | $16.95B |
Volume | 4,392,324 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $215.88 | $103.98 |
52-Week Low | $91.88 | $79.58 |
Typical Hold Time | 105 Days | 89 Days |
Enterprise Value | $11.02B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lululemon (LULU) stock trades at $92.68, down 54% year-to-date and near its 52-week low. The technical outlook is bearish, while fundamentals show strong profitability with a 56.11% gross margin and a low P/E of 7.63. Recent earnings beats are overshadowed by a revenue decline and multiple securities fraud investigations announced in late September 2026.
The stock presents a value opportunity based on depressed valuation multiples, but significant risks exist from legal scrutiny, competitive pressures, and weakening growth. Analyst consensus is a 'Hold' with a $97.67 price target, indicating cautious optimism amid high uncertainty.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
